Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)
Open Access
- 18 March 2013
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 42
Abstract
Background: Mucopolysaccharidosis II (MPS II, Hunter syndrome) is a rare X-linked lysosomal storage disorder caused by the deficiency of iduronate-2-sulfatase (IDS). In affected patients, glycosaminoglycan (GAG) accumulates in the lysosomes of many organs and tissues contributing to the pathology associated with MPS II. The objective of this phase I/II clinical study was to evaluate the efficacy and safety of recombinant human iduronate-2-sulfatase (idursulfase beta, Hunterase®) in the treatment of MPS II. Methods: Thirty-one MPS II patients between 6 and 35 years of age were enrolled in a randomized, single-blinded, active comparator-controlled phase I/II trial for 24 weeks. Patients were randomized to active comparator infusions (N=11), 0.5 mg/kg idursulfase beta infusions (N=10), or 1.0 mg/kg idursulfase beta infusions (N=10). The primary efficacy variable was the level of urinary GAG excretion. The secondary variables were changes in the distance walked in 6 minutes (6-minute walk test, 6MWT), echocardiographic findings, pulmonary function tests, and joint mobility. Results: Patients in all three groups exhibited reduction in urine GAG and this reduced GAG level was maintained for 24 weeks. Urine GAG was also significantly reduced in the 0.5 mg/kg and 1.0 mg/kg idursulfase beta groups when compared to the active comparator group (P = 0.043, 0.002, respectively). Changes in 6MWT were significantly greater in the 0.5 mg/kg and 1.0 mg/kg idursulfase groups than in the active comparator group (p= 0.003, 0.015, respectively). Both idursulfase beta infusions were generally safe and well tolerated, and elicited no serious adverse drug reactions. The most frequent adverse events were urticaria and skin rash, which were easily controlled with administration of antihistamines. Conclusions: This study indicates that idursulfase beta generates clinically significant reduction of urinary GAG, improvements in endurance as measured by 6MWT, and it has an acceptable safety profile for the treatment of MPS II. Trial registration: ClinicalTrials.gov: NCT01301898Keywords
This publication has 14 references indexed in Scilit:
- Identification of 11 novel mutations in 49 Korean patients with mucopolysaccharidosis type IIClinical Genetics, 2011
- Mutational spectrum of the iduronate 2 sulfatase gene in 25 unrelated Korean Hunter syndrome patients: Identification of 13 novel mutationsHuman Mutation, 2003
- ATS Statement: Guidelines for the Six-Minute Walk TestAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Ambulatory Blood Pressure and Left Ventricular Mass Index in Hypertensive ChildrenHypertension, 2002
- Long‐term follow‐up following bone marrow transplantation for Hunter diseaseJournal of Inherited Metabolic Disease, 1999
- Molecular analysis in 23 Hunter disease familiesJournal of Inherited Metabolic Disease, 1997
- Molecular and phenotypic variation in patients with severe Hunter syndromeHuman Molecular Genetics, 1997
- Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and impact of overweightJACC, 1992
- Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findingsThe American Journal of Cardiology, 1986
- Mild form of Hunter's syndrome: clinical delineation based on 31 cases.Archives of Disease in Childhood, 1982